DMF significantly reduced the odds of having a higher number of gadolinium-enhancing lesions by @ % ( BID ) and @ % ( TID ) and the mean number of new or enlarging T@ lesions by @ % ( BID ) and @ % ( TID ) , from the first post-baseline magnetic resonance imaging assessment at @weeks ( all P < @ versus placebo ) .